Gedeon Richter PLC (RGEDF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gedeon Richter PLC (RGEDF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 53/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 15. März 2026Gedeon Richter PLC (RGEDF) Gesundheitswesen & Pipeline-Uebersicht
Gedeon Richter PLC, a Hungarian pharmaceutical company with a rich history, focuses on developing, manufacturing, and marketing pharmaceutical products. With a diverse portfolio and a global presence, the company leverages its research and development capabilities and established distribution networks to maintain its market position within the healthcare sector.
Investmentthese
Gedeon Richter PLC presents a compelling investment case based on its established market position, diversified product portfolio, and attractive dividend yield of 4.28%. The company's consistent profitability, reflected in a 25.0% profit margin, and a low beta of 0.29 suggest stability. Growth catalysts include expansion into new therapeutic areas and strategic partnerships. However, investors may want to evaluate potential risks such as regulatory changes in the pharmaceutical industry and competition from generic drug manufacturers. The company's P/E ratio of 9.34 indicates a potentially undervalued stock relative to its earnings.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $5.67 billion, reflecting substantial investor confidence in Gedeon Richter's market position.
- Profit margin of 25.0%, indicating strong operational efficiency and profitability in the pharmaceutical sector.
- Gross margin of 68.1%, showcasing the company's ability to maintain high profitability on its products.
- Dividend yield of 4.28%, offering an attractive income stream for investors.
- Low beta of 0.29, suggesting lower volatility compared to the overall market, making it a potentially stable investment.
Wettbewerber & Vergleichsunternehmen
Staerken
- Established presence in Central and Eastern Europe.
- Diversified product portfolio across multiple therapeutic areas.
- Strong research and development capabilities.
- Attractive dividend yield.
Schwaechen
- Reliance on certain key products.
- Exposure to regulatory risks in the pharmaceutical industry.
- Limited presence in some major markets.
- Competition from larger pharmaceutical companies.
Katalysatoren
- Upcoming: Potential regulatory approvals for new pharmaceutical products in key markets.
- Ongoing: Expansion of the product portfolio through research and development.
- Ongoing: Strategic partnerships to enhance market reach and product offerings.
Risiken
- Potential: Increased competition from generic drug manufacturers.
- Potential: Regulatory changes impacting drug pricing and reimbursement.
- Ongoing: Patent expirations on key products.
- Ongoing: Fluctuations in currency exchange rates impacting international sales.
Wachstumschancen
- Expansion in Biosimilars: Gedeon Richter has the opportunity to expand its presence in the biosimilars market, capitalizing on the increasing demand for cost-effective alternatives to branded biologics. The global biosimilars market is projected to reach $100 billion by 2025. Richter's existing expertise in pharmaceutical manufacturing and its established distribution network position it well to capture a significant share of this growing market. This expansion could involve developing new biosimilars or partnering with other companies to commercialize existing products.
- Geographic Expansion: Gedeon Richter can further expand its geographic footprint, particularly in emerging markets with growing healthcare needs. These markets offer significant growth potential due to increasing disposable incomes and improving healthcare infrastructure. Focus on regions like Southeast Asia and Latin America could drive revenue growth. This expansion strategy may involve establishing local partnerships, setting up manufacturing facilities, or acquiring existing businesses.
- Strategic Partnerships and Acquisitions: Gedeon Richter can pursue strategic partnerships and acquisitions to expand its product portfolio and access new technologies. Collaborating with biotechnology companies or acquiring smaller pharmaceutical firms can provide access to innovative therapies and strengthen its competitive position. These partnerships could focus on co-development, licensing agreements, or joint marketing initiatives.
- Focus on Women's Healthcare: Gedeon Richter has a strong presence in women's healthcare and can further capitalize on this area by developing new products and expanding its existing portfolio. The global women's health market is expected to grow significantly in the coming years, driven by increasing awareness of women's health issues and advancements in medical technology. This could involve developing new contraceptives, hormone therapies, or treatments for gynecological conditions.
- Investment in Research and Development: Gedeon Richter can drive future growth by investing in research and development to discover and develop innovative therapies. Focusing on areas with unmet medical needs, such as oncology and neurology, can lead to the development of blockbuster drugs and create significant value for the company. This investment should focus on novel drug targets, advanced drug delivery systems, and personalized medicine approaches.
Chancen
- Expansion into biosimilars market.
- Geographic expansion into emerging markets.
- Strategic partnerships and acquisitions.
- Focus on women's healthcare.
Risiken
- Increasing competition from generic drug manufacturers.
- Pricing pressures and reimbursement challenges.
- Patent expirations on key products.
- Changes in healthcare regulations.
Wettbewerbsvorteile
- Established brand reputation and long history in the pharmaceutical industry.
- Strong research and development capabilities.
- Extensive distribution network across multiple countries.
- Focus on specialized therapeutic areas, such as women's healthcare.
Ueber RGEDF
Chemical Works of Gedeon Richter Plc, founded in 1901 by Gedeon Richter in Budapest, Hungary, is a pharmaceutical company engaged in the research, development, manufacture, and sale of pharmaceutical products. Initially focused on producing organotherapeutic drugs, the company expanded its portfolio over the years to include a wide range of therapeutic areas, including gynecology, central nervous system, and cardiovascular products. Richter operates through three main segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceutical segment is the core of the business, encompassing R&D, manufacturing, sales, and marketing. The Wholesale & Retail segment manages the distribution network through company-owned and partner pharmacies, ensuring product availability to consumers. The Other segment provides marketing and sales support services. Richter has a significant international presence, with subsidiaries and partnerships across Europe, Asia, and Latin America. The company is committed to innovation and invests heavily in research and development to bring new and improved treatments to market, maintaining a strong position in the competitive pharmaceutical landscape.
Was das Unternehmen tut
- Develops and manufactures pharmaceutical products.
- Engages in research and development activities.
- Markets and sells pharmaceutical products globally.
- Distributes products through wholesale and retail channels.
- Provides marketing and sales support services.
- Focuses on therapeutic areas such as gynecology, central nervous system, and cardiovascular diseases.
Geschaeftsmodell
- Develops and manufactures pharmaceutical products in-house.
- Sells products through a combination of direct sales and distribution partnerships.
- Generates revenue from the sale of prescription and over-the-counter drugs.
- Reinvests a portion of revenue into research and development to create new products.
Branchenkontext
Gedeon Richter PLC operates in the global pharmaceutical industry, a sector characterized by intense competition, stringent regulations, and continuous innovation. The market is driven by factors such as aging populations, increasing prevalence of chronic diseases, and advancements in medical technology. Key competitors include both multinational giants and regional players. Gedeon Richter's focus on specialized therapeutic areas and its established presence in Central and Eastern Europe provide a competitive edge. The industry is also witnessing a rise in biosimilars and generic drugs, impacting pricing and market share dynamics.
Wichtige Kunden
- Hospitals and clinics
- Pharmacies and drugstores
- Wholesale distributors
- Patients (indirectly through prescriptions)
Finanzdaten
Chart & Info
Gedeon Richter PLC (RGEDF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Highs On Wednesday
· 19. Feb. 2020
-
Stocks That Hit 52-Week Highs On Friday
· 10. Jan. 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer RGEDF.
Kursziele
Wall-Street-Kurszielanalyse fuer RGEDF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von RGEDF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Gabor Orban
CEO
Gabor Orban serves as the Chief Executive Officer of Gedeon Richter PLC. His background includes extensive experience in the pharmaceutical industry, with a focus on strategic management and business development. He has been with Gedeon Richter for a significant period, holding various leadership positions before assuming the role of CEO. His expertise spans across areas such as sales, marketing, and corporate strategy. He is responsible for overseeing the company's global operations and driving its growth initiatives.
Erfolgsbilanz: Under Gabor Orban's leadership, Gedeon Richter PLC has focused on expanding its international presence and strengthening its product portfolio through strategic acquisitions and partnerships. He has overseen the launch of several key products and has been instrumental in driving the company's innovation efforts. His tenure has been marked by a focus on sustainable growth and enhancing shareholder value.
RGEDF OTC-Marktinformationen
The OTC Other tier, also known as the Pink Market, represents the lowest tier of the over-the-counter (OTC) market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier have minimal listing requirements and may not be required to meet specific financial standards. This tier often includes companies that are distressed, penny stocks, or foreign companies that do not meet the listing requirements of major exchanges. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for fraud and market manipulation.
- Low trading volume and liquidity.
- Wider bid-ask spreads and price volatility.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investments.
- Established history of operations (founded in 1901).
- Presence in the pharmaceutical industry.
- Market capitalization of $5.67 billion.
- Operations in multiple countries.
- Availability of some financial information (e.g., market cap, P/E ratio).
Haeufige Fragen zu RGEDF
What are the key factors to evaluate for RGEDF?
Gedeon Richter PLC (RGEDF) currently holds an AI score of 53/100, indicating moderate score. Key strength: Established presence in Central and Eastern Europe.. Primary risk to monitor: Potential: Increased competition from generic drug manufacturers.. This is not financial advice.
How frequently does RGEDF data refresh on this page?
RGEDF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven RGEDF's recent stock price performance?
Recent price movement in Gedeon Richter PLC (RGEDF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established presence in Central and Eastern Europe.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider RGEDF overvalued or undervalued right now?
Determining whether Gedeon Richter PLC (RGEDF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying RGEDF?
Before investing in Gedeon Richter PLC (RGEDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding RGEDF to a portfolio?
Potential reasons to consider Gedeon Richter PLC (RGEDF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Established presence in Central and Eastern Europe.. Additionally: Diversified product portfolio across multiple therapeutic areas.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of RGEDF?
Yes, most major brokerages offer fractional shares of Gedeon Richter PLC (RGEDF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track RGEDF's earnings and financial reports?
Gedeon Richter PLC (RGEDF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for RGEDF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.